Biotechnology
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH
BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting onDecember 11-14, 2021, which will be hold o...
2021-11-09 13:06
2388
Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery
SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285...
2021-11-09 10:47
3008
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston
BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration. BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then...
2021-11-08 22:59
3158
Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer
SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced a clinical trial collaborati...
2021-11-08 21:47
2795
Farmmi Announces Latest Multi-Product Sales Win
LISHUI, China, Nov. 8, 2021 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI), an agriculture products supplier inChina, today announced the Company's subsidiary Zhejiang Farmmi Biotechnology Co., Ltd., won a new multi-product order for its popular dried black fungus and who...
2021-11-08 21:00
2029
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-11-08 20:00
3876
Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases
HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announce today that Ascletis' subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license agreement ou...
2021-11-08 08:30
4008
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...
2021-11-08 08:15
3603
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...
2021-11-08 08:10
2567
Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
SAN FRANCISCO and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...
2021-11-08 08:00
4093
Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
* The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo * The trial also showed that 77.1% of study participants who received Wegovy™ lost at least 5% of their bo...
2021-11-05 20:58
3291
PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline
* Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for predicting future decline in kidney function in patients with type 2 diabetes * PromarkerD correctly identified 84% of patients with normal kidney function that went on to experience kidney f...
2021-11-05 20:37
2446
New Data at ASH 2021 Reinforces the Strength of Servier's Hematology Portfolio
First Phase 3 results from the AGILE trial in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation show improved event-free survival and various secondary outcomes, including complete remission, overall survival and objective response rate, with ivosidenib tablets (TIBSOVO®)...
2021-11-05 08:05
3854
EpiVax licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition
PROVIDENCE, R.I., Nov. 4, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. ("Maruho") for EpiVax's patented Tregitope technology. This marks an exciting step for Maruho and EpiVax towards continued expansion of t...
2021-11-04 21:27
3062
Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting
SUZHOU and SHANGHAI, China, and PALO ALTO, California, Nov. 4, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2021-11-04 21:05
2444
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021
* Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie * Initial clinical results of lemzoparlimab in combination with rituximab in NHL will be presented at the ASH 2021 Annual Meeting * I-Mab to host a call for inves...
2021-11-04 21:00
2130
Taizhou, China: Building a Famous Chinese Medical City with Efforts
TAIZHOU, China, Nov. 4, 2021 /PRNewswire/ -- Recently, the 12th China (Taizhou) International Medical Expo was held inChina Medical City in Taizhou, China. Starting from the needs of normalized prevention and control of the epidemic, this year's expo made an "online+on-site" integrated exhibition...
2021-11-04 20:16
1660
Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of African Swine Fever Virus in Swine Whole Blood and Spleen Samples
ROCKVILLE, Md., Nov. 4, 2021 /PRNewswire/ -- Tetracore, Inc. (Tetracore) announced today the licensing of their VetAlert™ African Swine Fever Virus (ASFV) DNA Diagnostic Test Kit by the United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB). It is the first USDA l...
2021-11-04 20:02
3598
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
MELBOURNE, Australia, Nov. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studie...
2021-11-04 19:30
2286
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, Nov. 4, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-11-04 17:00
4565
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 287 media titles]
2026-05-26 10:30
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 285 media titles]
2026-05-27 09:16
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
8900
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8555
